Research on pharmacological activity of shikonin combined with low-intensity pulsed ultrasound to modulate ERK-JNK/NF-κB signaling pathway to inhibit arthritis

doi:10.16138/j.1673-6087.2024.06.06

Abstract

Abstract:

Objective To investigate the possible mechanism of shikonin in inhibiting synovial cell proliferation and inflammatory response and the effect of combining with low-intensity pulsed ultrasound (LI-PUS) in the treatment of rheumatoid arthritis. Methods Abnormal proliferation of mouse synoviocytes were induced by lipopolysaccharide (LPS) in vitro experiments. CCK-8 and ELISA were performed to detect the proliferation of synoviocytes and the expression levels of inflammatory factors and antioxidants. Cell scratch assay was used to detect the migration of synoviocytes. Immunofluorescence was used to detect the expression of nuclear factor (NF)-κB in synoviocytes. In vivo experiments, a mouse rheumatoid arthritis (RA) model was induced by complete Freund’s adjuvant. Forty mice were equally divided into 4 groups, which were normal group, model control group, shikonin perilla treatment group, and shikonin perilla+LI-PUS combination treatment group. The arthritic swelling indexes of the mice were recorded in day 12 and day 24 of treatment. At the end of the experiment, the serum levels of inflammatory factors were tested, and the expression levels of c-Jun N-terminal protein kinase (JNK), extracellular signal-regulated kinase (ERK), and NF-κB in the synovial tissues of the knee joints in mice were detected by Western blot. Results Shikonin inhibited the expression of inflammatory cytokines in LPS-induced synoviocytes. Shikonin intervention was able to significantly reverse LPS-induced oxidative stress in synoviocytes. The migration of synoviocytes were significantly inhibited under the intervention of different concentrations of shikonin. The level of NF-κB protein expression in synovial cells was reduced after the intervention of shikonin. The results of animal experiments showed that adjuvant-induced arthritis mice had significantly higher joint swelling scores, which could be significantly reduced after the intervention of shikonin. Shikonin+LI-PUS group showed good therapeutic effect on mice. Shikonin inhibited the expression of inflammatory cytokines, in which IL-1β was significantly reduced, and the combination of shikonin+LI-PUS showed highly significant anti-inflammatory effect. Western blot results showed that the phosphorylation content of ERK, JNK and NF-κB in the synovial tissue of mice in the model group was significantly higher than that in the normal group, which was significantly suppressed in the shikonin group and the shikonin+LI-PUS combination treatment group, and the shikonin+LI-PUS combination treatment group was superior to the shikonin group. Conclusions Shikonin can inhibit LPS-induced abnormal proliferation of synoviocytes and exert anti-arthritic activity through the ERK-JNK/NF-κB signaling pathway, and the combination of traditional Chinese medicine and low-intensity pulsed ultrasound is superior to the treatment of traditional Chinese medicine alone.

Key words: Shikonin, Low-intensity pulsed ultrasound, Arthritis, ERK-JNK/NF-κB

CLC Number:

R593.2

LIU Xiaoxu, LIU Jinyu, ZHOU Benyuan, FAN Kaijian. Research on pharmacological activity of shikonin combined with low-intensity pulsed ultrasound to modulate ERK-JNK/NF-κB signaling pathway to inhibit arthritis[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(06): 385-392.

Figures/Tables 11

Table 1

Table 2

Table 3

Table 4

Table 5

Figure 1

Figure 2

Table 6

Table 7

Figure 3

Table 8

References 22

[1]	Luo R, Su J, Zhang W, et al. Targeted delivery of NO donor and ROS scavenger for synergistic treatment of rheumatoid arthritis[J]. Biomed Pharmacother, 2024, 174:116540.
[2]	Li J, Tang RS, Shi Z, et al. Nuclear factor-κB in rheumatoid arthritis[J]. Int J Rheum Dis, 2020, 23(12):1627-1635.
[3]	Liu C, He L, Wang J, et al. Anti-angiogenic effect of Shikonin in rheumatoid arthritis by downregulating PI3K/AKT and MAPKs signaling pathways[J]. J Ethnopharmacol, 2020, 260:113039.
[4]	Soeken KL, Miller SA, Ernst E. Herbal medicines for the treatment of rheumatoid arthritis: a systematic review[J]. Rheumatology (Oxford), 2003, 42(5):652-659.
[5]	Singh S, Singh TG, Mahajan K, et al. Medicinal plants used against various inflammatory biomarkers for the management of rheumatoid arthritis[J]. J Pharm Pharmacol, 2020, 72(10):1306-1327. doi: 10.1111/jphp.13326 pmid: 32812250
[6]	Liu FY, Wang MQ, Liu MM, et al. Therapeutic effects of shikonin on adjuvant-induced arthritis in rats and cellular inflammation, migration and invasion of rheumatoid fibroblast-like synoviocytes via blocking the activation of Wnt/β-catenin pathway[J]. Phytomedicine, 2023, 116:154857.
[7]	Guo Y, Zhou M, Mu Z, et al. Recent advances in shikonin for the treatment of immune-related diseases: anti-inflammatory and immunomodulatory mechanisms[J]. Biomed Pharmacother, 2023, 165:115138.
[8]	Dai Q, Fang J, Zhang FS. Dual role of shikonin in early and late stages of collagen type Ⅱ arthritis[J]. Mol Biol Rep, 2009, 36(6):1597-1604.
[9]	He L, Luan H, He J, et al. Shikonin attenuates rheumatoid arthritis by targeting SOCS1/JAK/STAT signaling pathway of fibroblast like synoviocytes[J]. Chin Med, 2021, 16(1):96.
[10]	Yang KY, Chen DL. Shikonin inhibits inflammatory response in rheumatoid arthritis synovial fibroblasts via lncRNA-NR024118[J]. Evid Based Complement Alternat Med, 2015, 2015:631737.
[11]	Sun WX, Liu Y, Zhou W, et al. Shikonin inhibits TNF-α production through suppressing PKC-NF-κB-dependent decrease of IL-10 in rheumatoid arthritis-like cell model[J]. J Nat Med, 2017, 71(2):349-356.
[12]	Fu D, Shang X, Ni Z, et al. Shikonin inhibits inflammation and chondrocyte apoptosis by regulation of the PI3K/Akt signaling pathway in a rat model of osteoarthritis[J]. Exp Ther Med, 2016, 12(4):2735-2740. pmid: 27703516
[13]	Zachs DP, Offutt SJ, Graham RS, et al. Noninvasive ultrasound stimulation of the spleen to treat inflammatory arthritis[J]. Nat Commun, 2019, 10(1):951. doi: 10.1038/s41467-019-08721-0 pmid: 30862842
[14]	Prabhakar A, Banerjee R. Nanobubble liposome complexes for diagnostic imaging and ultrasound-triggered drug delivery in cancers: a theranostic approach[J]. ACS Omega, 2019, 4(13):15567-15580. doi: 10.1021/acsomega.9b01924 pmid: 31572858
[15]	Liao AH, Chung HY, Chen WS, et al. Efficacy of combined ultrasound-and-microbubbles-mediated diclofenac gel delivery to enhance transdermal permeation in adjuvant-induced rheumatoid arthritis in the rat[J]. Ultrasound Med Biol, 2016, 42(8):1976-1985.
[16]	Jie SS, Sun HJ, Liu JX, et al. Simiao Yong’an decoction ameliorates murine collagen-induced arthritis by modulating neutrophil activities: an in vitro and in vivo study[J]. J Ethnopharmacol, 2023, 305:116119.
[17]	Pinto BI, Cruz ND, Lujan OR, et al. In vitro scratch assay to demonstrate effects of arsenic on skin cell migration[EB/J]. J Vis Exp, 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC7537821/.
[18]	Bai Y, Li Y, Marion T, et al. Resistant starch intake alleviates collagen-induced arthritis in mice by modulating gut microbiota and promoting concomitant propionate production[J]. J Autoimmun, 2021, 116:102564.
[19]	Wang M, Su T, Sun H, et al. Regulating Th17/Treg balance contributes to the therapeutic effect of ziyuglycoside i on collagen-induced arthritis[J]. Int J Mol Sci, 2022, 23(24):16105.
[20]	Wang Y, Yan H, et al. An integrated network pharmacology approach reveals that Darutigenol reduces inflammation and cartilage degradation in a mouse collagen-induced arthritis model by inhibiting the JAK-STAT3 pathway[J]. J Ethnopharmacol, 2023, 314:116574.
[21]	Lin Z, Miao J, Zhang T, et al. JUNB-FBXO21-ERK axis promotes cartilage degeneration in osteoarthritis by inhibiting autophagy[J]. Aging Cell, 2021, 20(2):e13306.
[22]	Sun K, Hou L, Guo Z, et al. JNK-JUN-NCOA4 axis contributes to chondrocyte ferroptosis and aggravates osteoarthritis via ferritinophagy[J]. Free Radic Biol Med, 2023, 200:87-101.

紫草素（μmol/mL）	细胞活力（%）	P
0	100.00
5	97.25±1.58	0.955 5
10	95.25±0.69	0.920 6
15	94.25±1.15	0.315 5
20	93.54±1.06	0.077 1
25	91.24±1.38^1）	0.017 7
30	89.26±1.76^2）	0.000 2
35	81.26±1.26^2）	<0.000 1
40	75.25±1.97^2）	<0.000 1
45	73.69±1.68^2）	<0.000 1
50	66.95±1.82^2）	<0.000 1

LPS（ng/mL）	细胞活力（%）	P
0	100.00
1	102.84±1.24	0.999 8
2	105.29±1.18	0.267 2
4	107.84±2.03^1）	0.004 6
8	112.57±1.35^1）	<0.000 1
10	106.88±1.27	0.071 1
20	104.56±1.18	0.090 8

组别	细胞活力（%）	P
正常组	100.00
对照组	114.26±2.19¹⁾	0.001 1
LPS＋紫草素(40 μmol/mL)组	75.69±2.08²⁾	<0.000 1
LPS＋紫草素(50 μmol/mL)组	62.85±1.96²⁾	<0.000 1

组别	IL-1β	IL-6	TNF-α
正常组	74.26±4.29	94.26±5.86	68.57±4.59
对照组	129.86±5.84^1）	138.57±6.85^1）	128.75±7.26^1）
LPS（8 ng/mL）＋紫草素(40 μmol/mL)组	88.96±4.75^2）	104.25±3.96^2）	94.52±5.29^2）
LPS（8 ng/mL）＋紫草素(50 μmol/mL)组	67.85±3.58^2）	82.24±4.56^2）	72.74±4.26^2）

组别	SOD （U/mL）	MDA （nmol/mL）	GSH （μmol/gprot）
正常组	24.26±3.46	21.59±3.69	71.26±4.15
对照组	12.51±4.59^1）	36.26±4.26^1）	42.12±6.23^1）
LPS（8 ng/mL）＋紫草素(40 μmol/mL)组	18.26±4.16^2）	27.96±4.51^2）	57.12±3.96^2）
LPS（8 ng/mL）＋紫草素(50 μmol/mL)组	21.25±3.56^2）	22.86±5.76^2）	67.12±4.29^2）